Intercept Pharmaceuticals (ICPT) Upgraded to “Buy” by BidaskClub

BidaskClub upgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a hold rating to a buy rating in a research report report published on Wednesday morning.

A number of other equities research analysts also recently issued reports on the company. Wedbush reissued a buy rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, January 5th. Goldman Sachs downgraded Intercept Pharmaceuticals from a neutral rating to a sell rating in a research report on Wednesday, February 7th. Zacks Investment Research raised Intercept Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, January 16th. Citigroup set a $74.00 price target on Intercept Pharmaceuticals and gave the company a hold rating in a research report on Thursday, December 21st. Finally, Deutsche Bank started coverage on Intercept Pharmaceuticals in a research report on Monday, February 12th. They set a buy rating and a $103.00 price target for the company. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $128.90.

How to Become a New Pot Stock Millionaire

Intercept Pharmaceuticals stock opened at $71.98 on Wednesday. The firm has a market capitalization of $2,171.68, a P/E ratio of -5.01 and a beta of -1.82. Intercept Pharmaceuticals has a 52 week low of $51.05 and a 52 week high of $135.59. The company has a quick ratio of 4.31, a current ratio of 4.31 and a debt-to-equity ratio of 21.71.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.39) by ($1.04). The business had revenue of $37.69 million during the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. The business’s revenue for the quarter was up 173.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($4.84) earnings per share. research analysts predict that Intercept Pharmaceuticals will post -12.54 EPS for the current year.

In other Intercept Pharmaceuticals news, Director Keith Michael Gottesdiener purchased 1,171 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, April 9th. The stock was purchased at an average price of $64.00 per share, with a total value of $74,944.00. Following the completion of the acquisition, the director now owns 5,001 shares of the company’s stock, valued at approximately $320,064. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Francesco Micheli purchased 390,625 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, April 9th. The stock was acquired at an average cost of $64.00 per share, with a total value of $25,000,000.00. The disclosure for this purchase can be found here. Insiders bought 399,608 shares of company stock valued at $25,574,912 in the last ninety days. Company insiders own 9.20% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of Montreal Can boosted its holdings in Intercept Pharmaceuticals by 15.8% in the fourth quarter. Bank of Montreal Can now owns 19,073 shares of the biopharmaceutical company’s stock valued at $1,115,000 after purchasing an additional 2,603 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Intercept Pharmaceuticals by 68.6% in the third quarter. Cubist Systematic Strategies LLC now owns 6,717 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 2,734 shares during the last quarter. Legal & General Group Plc boosted its holdings in Intercept Pharmaceuticals by 48.2% in the third quarter. Legal & General Group Plc now owns 8,856 shares of the biopharmaceutical company’s stock valued at $514,000 after purchasing an additional 2,882 shares during the last quarter. DSC Advisors L.P. purchased a new position in Intercept Pharmaceuticals in the fourth quarter valued at about $204,000. Finally, Amalgamated Bank purchased a new position in Intercept Pharmaceuticals in the fourth quarter valued at about $209,000. 64.31% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Intercept Pharmaceuticals (ICPT) Upgraded to “Buy” by BidaskClub” was first reported by Week Herald and is the property of of Week Herald. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://weekherald.com/2018/04/19/intercept-pharmaceuticals-icpt-upgraded-to-buy-by-bidaskclub.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply